Can a new MS drug help you walk better and avoid falls?

NCT ID NCT06629428

Recruiting now Disease control Sponsor: Georgia State University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether ublituximab, a drug for relapsing multiple sclerosis, can improve walking function and reduce fall risk. Twenty-five participants will receive the drug for 48 weeks, with walking, disability, and thinking tests before, during, and after treatment. They will also be exposed to a simulated slip on a treadmill to see how well they recover.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ublituximab
What this could lead to: If it works, this could show that ublituximab improves walking and reduces falls in people with relapsing MS.
What could go wrong: This is a very small, early-phase study with only 25 participants, so results may not apply to everyone. It is designed to measure walking changes, not to prove long-term disease control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disease Progression relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS (MS) RELAPSING REMITTING

Contacts and locations

Locations

Atlanta Neuroscience Institute
RECRUITING

Atlanta, Georgia, 30327, United States
Georgia State University
NOT_YET_RECRUITING

Atlanta, Georgia, 30303, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.